%PDF-1.4
%
106 0 obj
<>
endobj
103 0 obj
<>
endobj
176 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-08-06T15:11:08Z
2024-03-29T01:58:46-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T01:58:46-07:00
application/pdf
Heather
2003-234.sept
uuid:c2cd76dd-1dd1-11b2-0a00-0109277d8900
uuid:c2cd76e0-1dd1-11b2-0a00-d30000000000
endstream
endobj
90 0 obj
<>
endobj
92 0 obj
<>
endobj
91 0 obj
<>
endobj
93 0 obj
<>
endobj
53 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 84 0 R/Type/Page>>
endobj
177 0 obj
[182 0 R]
endobj
178 0 obj
<>stream
q
0 0 612 783 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6283 0.7779 -0.7779 0.6283 8.2321 49.765 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 587 -785 re
W n
q
0 783.03 612 -783 re
W n
0 0 0 1 K
/GS1 gs
43 72 m
547 72 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 413.3613 53.9844 Tm
(The Journal of Rheumatology 2004; 31:9)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1708)Tj
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 2.55 84.8494 Td
(synovium demonstrates its potential for tendon destruction in)Tj
0 -1.25 TD
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 2001;44:1754-60.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (W)79.9 (esthof)17.7 (f CS, Freudiger D, Petrow P)110.7 (, et al. Characterization of)]TJ
2.175 -1.25 Td
(collagenase 3 \(matrix metalloproteinase 13\) messenger RNA)Tj
T*
(expression in the synovial membrane and synovial fibroblasts of)Tj
-0.0101 Tc T*
[(p)-10.1 (atients with rheumatoid arthritis. )54.6 (Arthritis Rheum 1999;42:1517-27.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Lindy O, Konttinen )36.8 (YT)73.9 (, Sorsa )17.7 (T)74 (, et al. Matrix metalloproteinase 13)]TJ
2.175 -1.25 Td
[(\(collagenase 3\) in human rheumatoid synovium. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1997;40:1391-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (V)128.9 (olck B. )36.8 (YKL-40 and the aminoterminal propeptide of type I)]TJ
2.175 -1.25 Td
[(procollagen, PINP)110.7 (, in patients with rheumatoid arthritis and)]TJ
T*
(osteoarthritis [dissertation]. Copenhagen: University of Copenhagen)Tj
0 Tc T*
(2000; 67 p.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875.1 (T)69.9 (akahashi M, Suzuki M, Naitou K, Miyamoto S, Kushida K.)]TJ
2.175 -1.25 Td
(Comparison of free and peptide-bound pyridinoline cross-links)Tj
T*
(excretion in rheumatoid arthritis and osteoarthritis. Rheumatology)Tj
T*
(Oxford 1999;38:133-8.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Cortet B, Flipo RM, Pigny P)110.7 (, et al. Is bone turnover a determinant)]TJ
-0.0101 Tc 2.175 -1.25 Td
(of bone mass in rheumatoid arthritis? J Rheumatol 1998;25:2339-44.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Sinigaglia L, )17.7 (V)110.8 (arenna M, Binelli L, et al. Urinary and synovial)]TJ
2.175 -1.25 Td
(pyridinium crosslink concentrations in patients with rheumatoid)Tj
T*
[(arthritis and osteoarthritis. )54.8 (Ann Rheum Dis 1995;54:144-7.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Gough )54.8 (A, Sambrook P)110.7 (, Devlin J, et al. Osteoclastic activation is the)]TJ
2.175 -1.25 Td
(principal mechanism leading to secondary osteoporosis in rheuma-)Tj
T*
(toid arthritis. J Rheumatol 1998;25:1282-9.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Furumitsu )36.8 (Y)128.9 (, Inaba M, )36.8 (Y)110.8 (ukioka K, et al. Levels of serum and)]TJ
2.175 -1.25 Td
(synovial fluid pyridinium crosslinks in patients with rheumatoid)Tj
T*
(arthritis. J Rheumatol 2000;27:64-70.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps)]TJ
2.175 -1.25 Td
(One Step ELISA. First application of monoclonal antibodies for)Tj
T*
(measurement in serum of bone-related degradation products from)Tj
T*
(C-terminal telopeptides of type I collagen. Clin Chem)Tj
0 Tc 0 Tw T*
(1998;44:2281-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Garnero P)110.7 (,)-0.1 ( Jouvenne P)110.7 (, Buchs N, Delmas PD, Miossec P)110.7 (.)]TJ
2.175 -1.25 Td
(Uncoupling of bone metabolism in rheumatoid arthritis patients)Tj
T*
(with or without joint destruction: assessment with serum type I)Tj
T*
(collagen breakdown products. Bone 1999;24:381-5.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Klarlund M, \257ster)17.7 (gaard M, Jensen KE, et al. Magnetic resonance)]TJ
2.175 -1.25 Td
[(imaging, radiography)64.8 (, and scintigraphy of the finger joints: one)]TJ
T*
[(year follow up of patients with early arthritis. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:521-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Jacobsen S, Madsen HO, Klarlund M, et al. )17.7 (The influence of)]TJ
2.175 -1.25 Td
(mannose binding lectin polymorphisms on disease outcome in early)Tj
T*
(polyarthritis. J Rheumatol 2001;28:935-42.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (W)79.9 (olfe F)79.7 (, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW)91.7 (, Freis)]TJ
2.175 -1.25 Td
[(FJ. )17.7 (The clinical value of the Stanford Health )54.8 (Assessment)]TJ
T*
(Questionnaire Functional Disability Index in patients with)Tj
T*
(rheumatoid arthritis. J Rheumatol 1988;15:1480-8.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )17.7 (The )54.8 (American college of)]TJ
2.175 -1.25 Td
(Rheumatology preliminary core set of disease activity measures for)Tj
T*
[(rheumatoid arthritis clinical trials. )17.7 (The Committee on Outcome)]TJ
T*
[(Measures in Rheumatoid )54.8 (Arthritis Clinical )17.7 (T)35 (rials. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1993;36:729-40.)Tj
-0.00011 Tc 0.02499 Tw 30.825 68.75 Td
[(30.)-875.1 (Orum O, Hansen M, Jensen CH, et al. Procollagen type I )]TJ
2.175 -1.25 Td
(N-terminal propeptide \(PINP\) as an indicator of type I collagen)Tj
T*
[(metabolism: ELISA)-220.2 (development, reference interval, and)]TJ
T*
(hypovitaminosis D induced hyperparathyroidism. Bone)Tj
0 Tc 0 Tw T*
(1996;19:157-63.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Jor)17.7 (gensen JT)73.9 (, )54.8 (Andersen PB, Rosholm )54.8 (A, Bjarnason NH. Digital )]TJ
2.175 -1.25 Td
(x-ray radiogrammetry: a new appendicular bone densitometric)Tj
T*
(method with high precision. Clin Physiol 2000;20:330-5.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Rosholm )54.8 (A, Hyldstrup L, B\276ksgaard L, Grunkin M, )17.7 (Thodber)17.7 (g HH.)]TJ
2.175 -1.25 Td
(Estimation of bone mineral density by digital X-ray)Tj
T*
[(radiogrammetry)64.8 (. )17.7 (Theoretical background and clinical setting.)]TJ
T*
(Osteoporosis Int 2001;12:961-9.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Larsen )54.8 (A, Dale K, Eek M. Radiographic evaluation of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis and related conditions by standard reference films. )54.8 (Acta)]TJ
T*
(Radiol Diagn 1977;18:481-91.)Tj
-2.175 -1.25 Td
[(34.)-875.1 (Matthews JNS, )54.8 (Altman DG, Campbell MJ, Royston P)110.7 (.)-0.1 ( )54.8 (Analysis of)]TJ
2.175 -1.25 Td
(serial measurements in medical research. BMJ 1990;300:230-5.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (Jensen )17.7 (T)74 (, Klarlund M, Hansen M, et al. Bone loss in unclassified)]TJ
2.175 -1.25 Td
(polyarthritis and early rheumatoid arthritis is better detected by)Tj
T*
[(digital x-ray radiogrammetry than dual x-ray absorptiometry)64.8 (.)]TJ
T*
[(Relationship to disease activity and radiographic outcome. )54.8 (Ann)]TJ
T*
(Rheum Dis 2004;63:15-22.)Tj
-2.175 -1.25 Td
[(36.)-875.1 (V)110.8 (an der Heijde DM, van Riel PL, van Leeuwen MA, van\325)17.7 (t Hof)]TJ
2.175 -1.25 Td
(MA, van Rijswijk MH, van de Putte LB. Prognostic factors for)Tj
T*
(radiographic damage and physical disability in early rheumatoid)Tj
T*
[(arthritis. )54.8 (A)-220.1 (prospective follow-up study of 147 patients. Br J)]TJ
0 Tc T*
(Rheumatol 1992,31:519-25.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(37.)-875.1 (Green MJ, Marzo-Ortega H, McGonagle D, et al. Persistence of)]TJ
2.175 -1.25 Td
(mild, early inflammatory arthritis: the importance of disease)Tj
T*
[(duration, rheumatoid factor and the shared epitope. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1999;42:2184-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(38.)-875.1 (Emery P)110.7 (.)-0.1 ( )17.7 (The Dunlop-Dottridge Lecture: Prognosis in inflammatory)]TJ
2.175 -1.25 Td
[(arthritis: )17.7 (The value of HLA)-220.2 (genotyping and the oncological)]TJ
T*
[(analogy)64.8 (. J Rheumatol 1997;24:1436-42.)]TJ
-2.175 -1.25 Td
[(39.)-875.1 (Emery P)110.7 (, Salmon M. Early rheumatoid arthritis: time to aim for)]TJ
0 Tc 2.175 -1.25 Td
[(remission? )54.9 (Ann Rheum Dis 1995;54:944-7.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(40.)-875.1 (Y)99.8 (oshihara )36.8 (Y)128.9 (, Obata K, Fujimoto N, )36.8 (Y)99.8 (amashita K, Hayakawa )17.7 (T)74.1 (,)]TJ
2.175 -1.25 Td
(Shimmei M. Increased levels of stromelysins-1 and tissue inhibitors)Tj
T*
(of metalloproteinases-1 in sera from patients with rheumatoid)Tj
T*
[(arthritis. )54.8 (Arthritis Rheum 1995;38:969-75.)]TJ
-2.175 -1.25 Td
[(41.)-875.1 (Cunnane G, FitzGerald O, Hummel KM, Gay RE, Gay S,)]TJ
2.175 -1.25 Td
[(Bresnihan B. Collagenase, cathepsin B and cathepsin L)-238.2 (gene)]TJ
T*
(expression in the synovial memebrane of patients with early)Tj
T*
(inflammatory arthritis. Rheumatology Oxford 1999;38:34-42.)Tj
-2.175 -1.25 Td
[(42.)-875.1 (Green MJ, Gough )54.8 (AKS, Devlin J, et al. Serum MMP-3 and MMP-1)]TJ
2.175 -1.25 Td
(and progression of joint damage in early rheumatoid arthritis.)Tj
T*
(Rheumatology Oxford 2003;42:83-8.)Tj
-2.175 -1.25 Td
[(43.)-875.1 (Manicourt DH, Fujimoto N, Obata K, )17.7 (Thonar EJ. Serum levels of)]TJ
2.175 -1.25 Td
[(collagenase, stromelysins-1, and )17.7 (TIMP-1. )54.8 (Age- and sex-related)]TJ
T*
[(dif)17.7 (ferences in normal subjects and relationship to the extent of joint)]TJ
T*
(involvement and serum levels of antigenic keratan sulfate in)Tj
T*
[(patients with osteoarthritis. )54.8 (Arthritis Rheum 1994;37:1774-83.)]TJ
-2.175 -1.25 Td
[(44.)-875.1 (Gough )54.8 (AK, Peel NF)79.7 (, Eastell R, Holder RL, Lilley J, Emery P)110.7 (.)]TJ
2.175 -1.25 Td
(Excretion of pyridinium crosslinks correlates with disease activity)Tj
T*
[(and appendicular bone loss in early rheumatoid arthritis. )54.8 (Ann)]TJ
T*
(Rheum Dis 1994;53:14-7.)Tj
ET
0 0 0 0 k
/GS0 gs
96.25 76.25 396.47 -10.83 re
f*
0.5 w
96.25 76.25 396.47 -10.83 re
S
Q
Q
q
0 0 612 783 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
110.368 69 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
84 0 obj
<>stream
8;Z\5!H-[H%-.@PkjPTg,a*3/>hZ66D2;C9%QQrn.>f&(3Ier_a$2aOnTg/`r9="R
rUBE6j%#$[>8(+;Hr0kfk]hL)5B*bUO9L5,'qgfXGV3fLW[M[+fbb<4PsnlpZb5Q9
BtT]#I,P5)&"P,[Bu!SbE1e7@YpZ1e*`-9UcD'kSBO>]_Ej,19K#HMNoJtML[4.N@
r13f5[4k_t3hh^p*Z#r>5\`ZWfq=Ma]LW<*._T")ZT0rYq]^UqJTAiZhTig'D0W_a
,&+SsP:\ttSK)RF!mVT5CD.#"23XG/e)V?e8t@!6(g0&/?;I;_[H.cqIOhEViL0>Y,2(9_=&m[1gZgAi\lEKn
9RZOs;eKmtannM[Hf8@UJDKL7#:7qGRC^6uZs!.i\f$E9["UCt)p>O?^=p;!h&U*B
F$UT>$D6$4QK8dW.@W&,?c(\PHE+AP,k&j*U#tj(7;_:Zq1>[D$RRphdUZ)5WNMPY
[+Eo-,`q?\VI/YiJj>04!F?tk2*gU]gWs[:U_\TtGKGg7-5JNjZfT$uR`-jVQFNF]
e"(.:\]NV3=(!gPro9bjNuCfoM=b.RmcRYR[`i
C/`6(RVlk4(*K`PQ0$3ek_!`B>W$.+Qi]64b]mXCh`V:[WnOjO_giKU&gei+#a,Dj
g*Dp!%A.Q9X-6rG.0>J#'N`[LJ]?C#bIdsmhHHaH]Cl!gLXN,.&RoS!@!):
endstream
endobj
88 0 obj
[/Indexed/DeviceRGB 255 87 0 R]
endobj
87 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
153 0 obj
<>
endobj
109 0 obj
<>
endobj
113 0 obj
<>
endobj
130 0 obj
<>
endobj
181 0 obj
<>
endobj
112 0 obj
<>
endobj
121 0 obj
<>stream
H|TPW}=Mό(=0%?QwEhDP48(ߙaDA(_ETP|DA#f\!ZZmL*~~u}B]ƈq]Z;#-0aEYYpJ+;쉵?%dG)ʈfebDPg%SX)B|cܥ:}!bWx;-ԅX`1;]zvhOq#R3uu&l&zGGF֠1jwe#341jCɮ{9ֆgaP"4_ϼ$DHL"k -G::PB TIF{}SHD#fk`(8* mm5(#5 tF / D&,q8qŖ-
UǫǗZ Zi<%$elobaB-mvt4O
;'ޥ:~e5L~ɪ'ڻا2ryaCc#HU
5;No9
XV]+ boZֺ_VD?{SNXW;0җ*CBUϜ P5uveRQbɣsbB B;r%bBr_rM~&+B^pRI$Op=9$Jh·n+i1vlLTd-O?1ڤ2Hh :Gc7Sa !ŁSp`7WfWfG%}ILs*s'13(= tiE⹄mE3+\H
?4.>Z 9ytX}|*fg]HCZiZ}tBܙ҃iMWb{m?Vm:Y\x:qڶ C[iu
%ZsYUP^,aOd7Os+ #l&Z0 aݍIX{ "v4bb
UJ'F-fb_l"bDCH='?SS͈m5QxM5ܥAUU}Lϫ8pWk)|ŖabpîkN
IVшU$_tHrgD37$nIن"OF%'$S5gzq悊zU,YE NYǧs]W*bǔCI!oizeC7c/.7ߑ[իܷy)L-TA++;noԝ4*em
-wASO3s1'̐O ~Pqoۣ)xD gVri)́!!pobL8vi03{0<)ڄ$]2?,i`=.OT+%e4!{6,c2%)v-v8k@
+/x\:/_\l:g4o?o^XĖEfxɧ
rΝO5s7NFQ|:j>U'o}KJLU#j@wlN:7/?'7W,y0Ycˊ9;U!cMs
,ۗ2{\Va_ԛQ=~
YF w˧S!Ҟ}{w[?[*40 F!/NXM
B+F<]UXy] _?T|4WXgI@])iZiZ+x,_:a)w@X]EgbӣbBH+#gW*>+ƫ[
Z}6JVF`hVxWQ!s]sKuF*@čM+L&zGWsBlg⿃t~<Rv>?_^8<Ǣ_mlxם~8(k]QM]Y=R:!{A[+.OZ_ QP&"r UюZE;ti3յ̜Nooow@|`\[_%Wd]$d?5dUmot8l|Жˉ*cL7NW%T+
}Ea/TGrĐ$&hm*j7Lj'MdҬ)6ZD5Ý\Yj#-pY` -u~S U}'p{|:X'7JOtδ)^Q}H^IWpQ!zjvR_}/Cٹ-z6xqhË6s7YǮ:\3a'%(
àf>v
a
3q`X;kB{0NyP(,c0 QBv&!c XBی{`!x"1($%6ja
lߦ%mji\yG~{,BIDJ-I 6JNkIJBF9_J"X/<c(K&3u5N`K\a0;/p`Xk^FT\ڢ:
>k˴tױRck,05Y;DXB]d4HvAH|nF|3&*cNb]-\$p֮jJjLuV"Lje⢚g1oi7q+qߚ+
b!T?T#ّS,AL0uM?vWnĐ贈Vyp`T.a=݇uz:adT"d8]]eyv+ޛ3Rf$ɜŰ |؝-I"UG
kWb,Ύ iN~7X*<,CHfP^mmqn_YQ]WOy:`#w|%SXtLq`=!
H}Iˢ8F'SRHHMP$gH|{1vcX]hLN-670sJxʤ7"89<`,aGuDb!o lm; ]y3lT<#B$&F0VY@⯺/Km/8&P5sع#?oPy}Éjt˟1
2-,á*8°!g?.eI(١
^BP{Tb8.D 8,[7 eC;bx2^x%_q(l+lpX0D;],3'\;LtOʮTu}+_bd{VW|p̀FK*Æ>Buwljxe#
vxŲH\,c9E>s}j\3=eN wӲGM&YDn*ÞHa {qʜ-(/(Tux%=ZRZ{"O%cDjeۦ_,H8nqoXE,m5BSy'(αQd<]b*YpeW%)*~A?eԤ=9R*f4U
.˘vبmsk